Taiyen Biotech Co (TPE:1737) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Taiyen Biotech Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Taiyen Biotech Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Taiyen Biotech Co's long-term debt to total assets ratio declined from Dec. 2023 (0.01) to Dec. 2024 (0.00). It may suggest that Taiyen Biotech Co is progressively becoming less dependent on debt to grow their business.

Taiyen Biotech Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Taiyen Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiyen Biotech Co LT-Debt-to-Total-Asset Chart

Taiyen Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

Taiyen Biotech Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	-

Taiyen Biotech Co LT-Debt-to-Total-Asset Calculation

Taiyen Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	31.488	/	8381.173
	=	0.00

Taiyen Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	31.488	/	8381.173
	=	0.00

Taiyen Biotech Co (TPE:1737) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Taiyen Biotech Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Taiyen Biotech Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiyen Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Taiyen Biotech Co Ltd (TPE:1737) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN

Website

https://www.tybio.com

Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.

Taiyen Biotech Co Headlines

No Headlines